Cellosaurus logo
expasy logo

Cellosaurus Daudi (CVCL_0008)

[Text version]
Cell line name Daudi
Synonyms DAUDI; NK-10A; NK-10a; NK 10a; NK10a; N; GM03190; GM3190; GM03190A; GM17346
Accession CVCL_0008
Resource Identification Initiative To cite this cell line use: Daudi (RRID:CVCL_0008)
Comments Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: Human variation panel.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Population: African; Kenyan.
Doubling time: 23.7 hours (PubMed=8847894); ~48 hours (DSMZ=ACC-78).
Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
Microsatellite instability: Instable (MSI-low) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Omics: Virome analysis using RNAseq.
Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620.
Misspelling: Duadi; Note=Occasionally.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: B-cell; CL=CL_0000236.
Sequence variations
  • Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=3116544; PubMed=6806672).
  • Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (PubMed=8197130; PubMed=11894933; Cosmic-CLP; DepMap).
  • Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (ATCC).
  • Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*01:02,66:01
HLA-BB*35:01,58:01
HLA-CC*03:02,06:02
Class II
HLA-DQDQA1*01:03,01:03
DQB1*06:13,06:13
HLA-DRDRB1*13:02,03:27

Source: PubMed=26589293
Class I
HLA-AA*01:02,66:01
HLA-BB*58:01,58:01
HLA-CC*03:02,06:02

Source: IPD-IMGT/HLA=10471
Class I
HLA-AA*01:02,66:01
HLA-BB*58:01:01:01,58:02:01
HLA-CC*03:02:02:01,06:02
Class II
HLA-DPDPA1*01:03:01,02:01:01:01
DPB1*02:01:02:01,106:01
HLA-DQDQA1*01:02,01:03
DQB1*06:04:01,06:02
HLA-DRDRB1*13:01:01,13:02:01
DRB3*02:02,03:01:01
DRB6*02

Source: DSMZCellDive=ACC-78
Class I
HLA-AA*01:02,66:01:01
HLA-BB*58:01:01,58:02:01
HLA-CC*03:02:02,06:02:01
Class II
HLA-DPDPA1*01:03:01,02:01:01
DPB1*02:01:02,106:01
HLA-DQDQA1*01:02:01,01:03:01
DQB1*06:09:01,06:02:01
HLA-DRDRA*01:01:01,01:02:03
DRB1*13:01:01,13:02:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African91.6
Native American0.12
East Asian, North2.24
East Asian, South0
South Asian1.3
European, North0
European, South4.74
Disease EBV-related Burkitt lymphoma (NCIt: C27694)
Burkitt lymphoma (ORDO: Orphanet_543)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_B5KW (Daudi-Luc2)CVCL_6220 (Daudi-TG)CVCL_UF09 (DIF10)
CVCL_UF10 (DIF2)CVCL_UF11 (DIF3)CVCL_UF14 (DIF8)
CVCL_UF15 (DIF9)CVCL_ZI16 (DUT)CVCL_5I55 (RST2)
Sex of cell Male
Age at sampling 16Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200; RCB; TKG

Markers:
AmelogeninX,Y
CSF1PO12
D2S133817,24
D3S135816,18
D5S8188,13
D7S8208,10
D8S117914
D13S31711,12
D16S53910,12
D18S5116,18
D19S43312,14
D21S1134,35
FGA21,26
Penta D10,12
Penta E7,9 (ATCC; DSMZ; PubMed=25877200)
9 (CCRID)
TH016,7
TPOX8,11
vWA15,17

Run an STR similarity search on this cell line
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=DAUDI
https://www.proteinatlas.org/learn/cellines
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/d/cell-lines-detail-87.html
https://tcpaportal.org/mclp/
Publications

PubMed=4174339
Klein E., Klein G., Nadkarni J.S., Nadkarni J.J., Wigzell H., Clifford P.
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.
Cancer Res. 28:1300-1310(1968)

PubMed=4878906; DOI=10.1084/jem.128.5.1011
Klein G., Pearson G.R., Nadkarni J.S., Nadkarni J.J., Klein E., Henle G., Henle W., Clifford P.
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus.
J. Exp. Med. 128:1011-1020(1968)

PubMed=4178827; DOI=10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M
Nadkarni J.S., Nadkarni J.J., Clifford P., Manolov G., Fenyo E.-M., Klein E.
Characteristics of new cell lines derived from Burkitt lymphomas.
Cancer 23:64-79(1969)

PubMed=4321974
Maurer B.A., Imamura T., Wilbert S.M.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970)

PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972)

PubMed=5021706
van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E., Clifford P.
Synthesis of immunoglobulins by biopsied tissues and cell lines from Burkitt's lymphoma.
Immunology 22:847-857(1972)

PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973)

PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975)

PubMed=216485
Higgins N.P., Strauss B.S.
Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.
Cancer Res. 39:312-320(1979)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6806672; DOI=10.1038/298474a0
Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.
Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.
Nature 298:474-476(1982)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6186604; DOI=10.1007/BF00364753
de Preval C., Mach B.
The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.
Immunogenetics 17:133-140(1983)

PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x
Rosa F.M., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M.
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.
EMBO J. 2:239-243(1983)

PubMed=6200433; DOI=10.1007/BF00364762
Brodsky F.M.
A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.
Immunogenetics 19:179-194(1984)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6547209; DOI=10.1038/309592a0
Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.
Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.
Nature 309:592-597(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=6592381; DOI=10.1093/jnci/73.4.841
Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F., Lenoir G.M.
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
J. Natl. Cancer Inst. 73:841-847(1984)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=2998993
Steel C.M., Morten J.E.N., Foster E.
The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
IARC Sci. Publ. 60:265-292(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3905596
Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C., Dore J.-F., Lenoir G.M.
Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging.
IARC Sci. Publ. 60:447-452(1985)

PubMed=3080238
Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.
Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Cancer Res. 46:1182-1188(1986)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3785169; DOI=10.1128/mcb.6.5.1374-1378.1986
Dron M., Modjtahedi N., Brison O., Tovey M.G.
Interferon modulation of c-myc expression in cloned Daudi cells: relationship to the phenotype of interferon resistance.
Mol. Cell. Biol. 6:1374-1378(1986)

PubMed=3026973; DOI=10.1002/ijc.2910390215
Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.
Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Int. J. Cancer 39:211-218(1987)

PubMed=3034807; DOI=10.1002/ijc.2910390622
Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S., Uchino H., Toyoshima K.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Int. J. Cancer 39:785-788(1987)

PubMed=3116544; DOI=10.1073/pnas.84.19.6835
Haluska F.G., Tsujimoto Y., Croce C.M.
The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region.
Proc. Natl. Acad. Sci. U.S.A. 84:6835-6839(1987)

PubMed=2470097; DOI=10.1073/pnas.86.9.3257
Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.
Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=8301159; DOI=10.1089/jir.1993.13.377
Dron M., Tovey M.G.
Interferon-resistant Daudi cells are deficient in interferon-alpha-induced ISGF3 alpha activation, but remain sensitive to the interferon-alpha-induced increase in ISGF3 gamma content.
J. Interferon Res. 13:377-383(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=8197130; DOI=10.1073/pnas.91.11.4751
Bicknell D.C., Rowan A.J., Bodmer W.F.
Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)

PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893
Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.
Deletions and rearrangement of CDKN2 in lymphoid malignancy.
Blood 85:893-901(1995)

PubMed=8558913
Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.
Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.
Leukemia 10:102-105(1996)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9192833
Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.
Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cancer Res. 57:2508-2515(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112
Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9973220
Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891
Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.
Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.
Leukemia 14:1821-1832(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=12145705; DOI=10.1038/sj.leu.2402519
Langerak A.W., Moreau E., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.
Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.
Leukemia 16:1572-1573(2002)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x
Kamimura K., Hojo H., Abe M.
Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.
Pathol. Int. 54:224-230(2004)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161
Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.
Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.
Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404
Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.
Screening human cell lines for viral infections applying RNA-Seq data analysis.
PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0003010/4669
ATCC; CCL-213
ATCC; CRL-7917 - Discontinued
BCRC; 60192
CCTCC; GDC0097
CLS; 302009
Coriell; GM03190
Coriell; GM17346
DSMZ; ACC-78
ECACC; 85011437
ECACC; 94071449
ICLC; HTL95024
IZSLER; BS TCL 104
JCRB; JCRB9071
KCB; KCB 2012116YJ
KCLB; 10213
NCBI_Iran; C112
RCB; RCB1640
TKG; TKG 0362
Cell line databases/resources CLO; CLO_0002708
CLO; CLO_0013411
CLO; CLO_0013740
CLO; CLO_0050991
MCCL; MCC:0000141
CLDB; cl993
CLDB; cl994
CLDB; cl995
CLDB; cl996
CLDB; cl997
CLDB; cl998
CLDB; cl999
CLDB; cl5181
cancercelllines; CVCL_0008
CCRID; 1101HUM-PUMC000134
CCRID; 1102HUM-NIFDC00053
CCRID; 3101HUMTCHu140
CCRID; 4201HUM-CCTCC00097
Cell_Model_Passport; SIDM00845
CGH-DB; 9195-4
Cosmic-CLP; 906831
dbMHC; 48767
DepMap; ACH-000786
DSMZCellDive; ACC-78
IGRhCellID; Daudi
IHW; IHW09366
IPD-IMGT/HLA; 10471
LINCS_LDP; LCL-2018
Lonza; 490
Anatomy/cell type resources BTO; BTO:0001561
Biological sample resources BioSample; SAMN00808283
BioSample; SAMN01821546
BioSample; SAMN01821623
BioSample; SAMN03472413
BioSample; SAMN10987948
CRISP screens repositories BioGRID_ORCS_Cell_line; 1081
Chemistry resources ChEMBL-Cells; CHEMBL3307579
ChEMBL-Targets; CHEMBL614281
GDSC; 906831
PharmacoDB; Daudi_283_2019
PubChem_Cell_line; CVCL_0008
Encyclopedic resources Wikidata; Q54828579
Experimental variables resources EFO; EFO_0002169
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM99381
GEO; GSM862859
GEO; GSM862860
GEO; GSM862861
GEO; GSM862862
GEO; GSM886973
GEO; GSM888042
GEO; GSM960117
GEO; GSM960118
GEO; GSM960119
GEO; GSM960120
GEO; GSM1374459
GEO; GSM1669726
GEO; GSM3150242
Polymorphism and mutation databases Cosmic; 687838
Cosmic; 906831
Cosmic; 919135
Cosmic; 929815
Cosmic; 931102
Cosmic; 932762
Cosmic; 991548
Cosmic; 996304
Cosmic; 998716
Cosmic; 1019315
Cosmic; 1037701
Cosmic; 1070708
Cosmic; 1071878
Cosmic; 1086326
Cosmic; 1093789
Cosmic; 1118470
Cosmic; 1176616
Cosmic; 1191690
Cosmic; 1517663
Cosmic; 1995384
Cosmic; 2649240
Cosmic; 2759407
Cosmic; 2760061
Cosmic; 2814537
Cosmic; 2815216
Cosmic; 2823073
IARC_TP53; 143
IARC_TP53; 21144
LiGeA; CCLE_233
Progenetix; CVCL_0008
Proteomic databases PRIDE; PXD004181
PRIDE; PXD012087
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number47